NeuroOne Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) announced on September 22, 2022, the approval of equity awards to new employees as part of the 2021 Inducement Plan. Effective September 20, 2022, these individuals were granted options to purchase 1,000 shares at an exercise price of $1.97, based on the closing stock price on the grant date. The options vest over four years, with 25% vesting after one year and the remainder vesting monthly after that, contingent on continuing employment.
- Granting of stock options may help attract and retain talent.
- Equity awards align employee interests with shareholder value.
- The equity awards may dilute existing shareholders' ownership.
EDEN PRAIRIE, Minn., Sept. 22, 2022 /PRNewswire/ -- NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders today announced that, effective September 20, 2022, the Compensation Committee of the Board of Directors approved two equity awards under the NeuroOne Medical Technologies Corporation 2021 Inducement Plan (the "Inducement Plan"), as a material inducement to the individuals entering into employment with the Company. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4), which also requires a public announcement of awards that are not made under a stockholder approved equity plan.
In connection with entering into employment with NeuroOne, the individuals, who were not previously employees or directors of NeuroOne, each received an option to purchase 1,000 shares of the Company's common stock. The option awards have an exercise price of
NeuroOne Medical Technologies Corporation is a developmental stage company committed to providing minimally invasive and hi-definition solutions for EEG recording, brain stimulation and ablation solutions for patients suffering from epilepsy, Parkinson's disease, dystonia, essential tremors, chronic pain due to failed back surgeries and other related neurological disorders that may improve patient outcomes and reduce procedural costs. For more information, visit https://www.n1mtc.com.
View original content to download multimedia:https://www.prnewswire.com/news-releases/neuroone-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-301630765.html
SOURCE NeuroOne Medical Technologies Corporation
FAQ
What equity awards did NeuroOne grant on September 20, 2022?
Under which plan were the equity awards at NeuroOne approved?
What is the vesting schedule for the options granted by NeuroOne?
How do the stock options impact NeuroOne shareholders?